In summary, this study provided novel insight into the mechanisms underlying the development of MGMT‐positive GBM and identified novel biomarkers for the development of MGMT‐positive GBM and MGMT‐negative GBM by using metabolomics and proteomics analyses. This evidence concerns the gene MGMT and glioblastoma.